ERAS peer analysis
Erasca (ERAS) against its competitors: price, today's move, 1-year return and market value side by side.
ERAS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AVBP ArriVent BioPharma | $13.52 | 10.58% | -26.22% | $666.82M |
| CRIS Curis | $0.78 | -8.00% | -97.25% | $1.90M |
| IDYA IDEAYA Biosciences | $31.24 | 1.92% | 5.33% | $3.02B |
| KURA Kura Oncology | $7.27 | 6.91% | -26.86% | $646.74M |
| NUVB Nuvation Bio | $4.19 | 0.00% | -14.84% | $1.48B |
| ORIC Oric | $8.82 | 3.89% | -28.76% | $914.22M |
| RVMD Revolution Medicines | $194.38 | 9.41% | 227.56% | $42.04B |
| TNGX Tango Therapeutics | $21.50 | 3.02% | 186.28% | $3.63B |
| VSTM Verastem | $8.40 | -10.45% | 2.94% | $1.06B |
| ERAS Erasca | $14.57 | 9.80% | 562.27% | $5.10B |
- ERAS's peers: AVBP (ArriVent BioPharma), CRIS (Curis), IDYA (IDEAYA Biosciences), KURA (Kura Oncology), NUVB (Nuvation Bio), ORIC (Oric), RVMD (Revolution Medicines), TNGX (Tango Therapeutics).
Updated 2026-11-07 11:53 UTC